Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 21 for:    remimazolam
Previous Study | Return to List | Next Study

Absolute Oral Bioavailability of Remimazolam

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04113564
Recruitment Status : Completed
First Posted : October 2, 2019
Last Update Posted : October 2, 2019
Sponsor:
Collaborator:
PRA Health Sciences
Information provided by (Responsible Party):
Paion UK Ltd.

Brief Summary:
A randomized, open-label, single-dose, 2-way crossover study to compare the relative bioavailability of orally administered remimazolam to an intravenous formulation in healthy volunteers

Condition or disease Intervention/treatment Phase
Bioavailability Drug: Remimazolam Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 14 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: A Randomized, Open-label, Single-dose, 2-way Crossover Study to Compare the Relative Bioavailability of Orally Administered Remimazolam to an Intravenous Formulation in Healthy Volunteers
Actual Study Start Date : November 3, 2015
Actual Primary Completion Date : November 20, 2015
Actual Study Completion Date : November 20, 2015

Arm Intervention/treatment
Experimental: IV remimazolam
IV remimazolam administration of 0.025 mg/kg body weight
Drug: Remimazolam
Other Name: CNS7056

Experimental: Oral remimazolam
Oral remimazolam Administration of 0.14 mg/kg Body weight
Drug: Remimazolam
Other Name: CNS7056




Primary Outcome Measures :
  1. Absolute oral bioavailability of remimazolam [ Time Frame: Day 1 (pre-dode) to Day 3 ]
    Single-dose bioavailability of an oral formulation of remimazolam relative to an IV formulation of remimazolam in healthy male and female subjects


Secondary Outcome Measures :
  1. Maximum Plasma concentration (Cmax) [ Time Frame: Day 1 (pre-dode) to Day 3 ]
    Maximum observed plasma concentration

  2. Time to Maximum Plasma concentration (Tmax) [ Time Frame: Day 1 (pre-dode) to Day 3 ]
    Time to attain maximum observed plasma concentration

  3. Area under the plasma concentration-time curve (AUC0-t) [ Time Frame: Day 1 (pre-dode) to Day 3 ]
    Area under the plasma concentration-time curve from time 0 up to the time of the last measurable concentration

  4. Elimination half-life (T1/2) [ Time Frame: Day 1 (pre-dode) to Day 3 ]
    Terminal elimination half-life

  5. Clearance (CL/F) [ Time Frame: Day 1 (pre-dode) to Day 3 ]
    Apparent oral clearance

  6. Volume of Distribution (Vz/F) [ Time Frame: Day 1 (pre-dode) to Day 3 ]
    Apparent volume of distribution at terminal phase

  7. Incidences of Treatment-emergent adverse events [ Time Frame: Day 1 (pre-dode) to Day 3 ]
    Incidences of Treatment-emergent adverse events



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Willing to participate in the study, willing to give written informed consent prior to the initiation of any protocol-specific procedures, and willing to comply with the study restrictions.
  2. Had to be able to speak, read, and understand English sufficiently to allow completion of all study assessments.
  3. Gender : males and/or females
  4. Age : 18 - 55 years, inclusive
  5. Body mass index (BMI) : 18.0 - 32.0 kg/m2
  6. Weight : ≥50 kg
  7. Healthy status was defined by the absence of evidence of any clinically significant, in the opinion of the Investigator, active or chronic disease following a detailed medical and surgical history, a complete physical examination including vital signs, 12-lead ECG, hematology, clinical chemistry, serology, and urinalysis.
  8. Ability and willingness to abstain from alcohol, caffeine, and xanthine-containing beverages or food (eg, coffee, tea, cola, chocolate, energy drinks) from 48 hours (2 days) prior to admission to the clinical facility on Day -1 until study discharge.
  9. All values for hematology and for clinical chemistry tests of blood and urine within the normal range or showing no clinically relevant deviations as judged by the Investigator.
  10. Females of childbearing potential and males and their female partner(s) of childbearing potential had to agree to use 2 forms of contraception, 1 of which had to be a barrier method, during the study and for 90 days after the last drug administration. Acceptable barrier forms of contraception were condom and diaphragm. Acceptable non-barrier forms of contraception for this study were an intrauterine device (IUD) and/or spermicide.
  11. For females: a negative pregnancy test at Screening and Day -1.
  12. Postmenopausal females: defined as 12 months with no menses prior to Screening and a serum follicle stimulating hormone (FSH) >40 IU/L at Screening.
  13. All non-regular medication (including over-the-counter [OTC] medication, health supplements, and herbal remedies such as St. John's Wort extract) must have been stopped at least 14 days prior to admission to the clinical research center. An exception was made for paracetamol (acetaminophen), which was allowed up to admission to the clinical research center.

Exclusion Criteria:

  1. Women who were pregnant or lactating.
  2. Males with female partners who were pregnant or lactating.
  3. Use of any investigational drug or device within 30 days of the first dose of study medication.
  4. Any disease which, in the opinion of the Investigator, posed an unacceptable risk to the subjects.
  5. Known allergy, hypersensitivity or prior intolerance to benzodiazepine derivates or flumazenil, or a medical condition such that these agents were contraindicated.
  6. The use of tobacco products within 60 days prior to the first drug administration.
  7. Routine or chronic use of more than 3 grams of acetaminophen daily.
  8. Strenuous activity, sunbathing and contact sports within 48 hours (2 days) prior to admission to the clinical facility and for the duration of the study.
  9. History of donation of more than 450 mL of blood within 60 days prior to dosing in the clinical research center or planned donation before 30 days had elapsed since intake of study drug.
  10. Plasma or platelet donation within 7 days of dosing and throughout the entire study.
  11. History of alcohol consumption exceeding 2 standard drinks per day on average (1 standard drink = 10 grams of alcohol). Alcohol consumption was prohibited from 48 hours prior to admission to the clinical facility and throughout the entire study until discharge.
  12. Positive screening test for hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (HCV) antibodies, or anti-human immunodeficiency virus (HIV) 1 and 2 antibodies.
  13. Positive results for drugs of abuse, including cotinine, in the urine at Screening or Day -1.
  14. Positive results for alcohol abuse, as determined by alcohol breath test, at Screening or Day -1.
  15. Inability to be venipunctured or tolerate venous access as determined by the Investigator or designee.
  16. History of clinically significant, recent/current and nonremote suicidal ideations or suicide attempts that, in the opinion of the Investigator, posed an unacceptable risk to the subject for participating in the study.
  17. Any major surgery within 4 weeks of study drug administration. NOTE: Any parameter/test could be repeated at the Investigator's discretion during Screening and/or on Day -1.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04113564


Locations
Layout table for location information
United States, Utah
PRA Health Sciences (PRA) - Early Development Services (EDS)
Salt Lake City, Utah, United States, 84106
Sponsors and Collaborators
Paion UK Ltd.
PRA Health Sciences
Investigators
Layout table for investigator information
Principal Investigator: Shawn Searle, MD PRA Health Sciences

Layout table for additonal information
Responsible Party: Paion UK Ltd.
ClinicalTrials.gov Identifier: NCT04113564     History of Changes
Other Study ID Numbers: CNS7056-016
First Posted: October 2, 2019    Key Record Dates
Last Update Posted: October 2, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No